CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −37,494 | 62,506 | ||
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −31,250 | 118,750 | ||
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +83,978 | $8.44 | $709K | 87,978 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +3,529 | $17.88 | $63K | 91,507 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −26,166 | $35.80 | $937K | 65,341 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −42,765 | $37.04 | $1.6M | 22,576 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −18,576 | $37.72 | $701K | 4,000 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −83,978 | 11,996 | ||
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,529 | 116,471 | ||
| 2025-09-30 | Garcia Marino CEO AND PRESIDENT | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2025-09-23 | Savitz Ryan CFO & CBO | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-09-23 | Randhawa Simrat CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-09-09 | Savitz Ryan CFO & CBO | Option exercise 10b5-1 | +20,000 | $8.44 | $169K | 20,000 |
| 2025-09-09 | Savitz Ryan CFO & CBO | Sale 10b5-1 | −20,000 | $35.00 | $700K | 0 |
| 2025-09-09 | Savitz Ryan CFO & CBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | +20,000 | 104,766 | ||
| 2025-05-22 | Violin Jonathan Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2025-05-22 | Soteropoulos Paula Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2025-05-22 | Romano Steven J. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2025-05-22 | McGeorge Anne Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2025-05-22 | Lawton Alison Frances Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 |
Page 10 of 24 · 470 trades